Glutathione S-Transferase P1 (GSTP1) and Retinoic Acid Receptor 2 (RARβ2) were selected as markers given that their methylation has been previously shown to be more prevalent in prostate cancer cells [6-8]. This evidence concerns the gene GSTP1 and prostate cancer.